About this Research Topic
RNA modification mechanisms and their related machineries are pivotal in determining cellular fate, dynamically regulating nearly every aspect of RNA functionality. A growing body of evidence suggests that variations in RNA modifications are implicated in a wide spectrum of physiological and pathological states, with cancer being of notable concern. These modifications selectively influence the translation of transcripts that can either promote or suppress tumor development, thereby playing a critical role in cancer progression. Consequently, the machinery responsible for RNA modification—specifically writers, readers, and erasers—has garnered significant interest for their therapeutic potential in disease management.
The primary objective of this research topic is to investigate the influence of RNA modifications, such as N 6-methyladenosine (m 6A), N 1-methyladenosine (m 1A), 5-methylcytosine (m 5C), N 7-methylguanosine (m 7G), N 4-acetylcytosine (ac 4C), pseudouridine (Ψ), and uridylation, on cancer immunity and the effectiveness of immunotherapies. This initiative aims to critically assess how these RNA modifications affect cancer development and to explore the possibility of targeting these modifications to improve the outcomes of cancer immunotherapy. By establishing a comprehensive research platform, this effort seeks to propel forward the development of more precise and potent cancer treatments through the innovative targeting of RNA modifications.
We welcome the submission of high-quality Systematic Reviews, Mini Reviews, Reviews, and Original Research including but not limited to, the following areas:
1) The role of RNA modification in cancer immunology and how RNA modification influences immune responses in cancer.
2) Proteins involved in RNA modification signaling, such as writers, erasers, and readers, and their functions in cancer immunity and immunotherapy.
3) Changes in RNA modification within the tumor immune microenvironment and how RNA modification mediates the complex interactions between tumor cells and the immune system.
4) The potential utility of RNA modification as biomarkers for cancer diagnosis, immunotherapy response, and prognosis.
5) Strategies for targeting RNA modification and related proteins for cancer immunotherapy.
The primary objective of this research topic is to investigate the influence of RNA modifications, such as N 6-methyladenosine (m 6A), N 1-methyladenosine (m 1A), 5-methylcytosine (m 5C), N 7-methylguanosine (m 7G), N 4-acetylcytosine (ac 4C), pseudouridine (Ψ), and uridylation, on cancer immunity and the effectiveness of immunotherapies. This initiative aims to critically assess how these RNA modifications affect cancer development and to explore the possibility of targeting these modifications to improve the outcomes of cancer immunotherapy. By establishing a comprehensive research platform, this effort seeks to propel forward the development of more precise and potent cancer treatments through the innovative targeting of RNA modifications.
We welcome the submission of high-quality Systematic Reviews, Mini Reviews, Reviews, and Original Research including but not limited to, the following areas:
1) The role of RNA modification in cancer immunology and how RNA modification influences immune responses in cancer.
2) Proteins involved in RNA modification signaling, such as writers, erasers, and readers, and their functions in cancer immunity and immunotherapy.
3) Changes in RNA modification within the tumor immune microenvironment and how RNA modification mediates the complex interactions between tumor cells and the immune system.
4) The potential utility of RNA modification as biomarkers for cancer diagnosis, immunotherapy response, and prognosis.
5) Strategies for targeting RNA modification and related proteins for cancer immunotherapy.
Keywords: RNA Modification, Cancer
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
